Page 55 - NobleCon19revC2_Neat

Cadrenal Therapeutics, Inc.

SELECTED FINANCIAL ITEMS CVKD

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (1.32) (4.20) (1.03) (1.14) (7.69)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (5.62) (5.17) (1.00) (1.04) (12.83)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 0.78 4.48 3.56 9.31 9.31
Cash & Short Term Investments 0.03 4.03 3.23 9.11 9.11
% of Assets 4% 90% 91% 98% 98%
Current Assets -Total 0.73 4.44 3.52 9.28 9.28
% of Assets 94% 99% 99% 100% 100%
Total Liabilities 6.33 0.42 0.38 0.57 0.57
% of Assets 813% 9% 11% 6% 6%
Current Liabilities - Total 1.33 0.40 0.37 0.56 0.56
% of Assets 171% 9% 11% 6% 6%
Long Term Debt 0.55 NA NA NA NA
% of Assets 71% NM NM NM NM
Total Equity (5.55) 4.07 3.18 8.75 8.75
% of Assets -713% 91% 89% 94% 94%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (0.40) (1.41) (0.80) (0.63) (3.24)
Net Cash Flow - Investing (0.00) NA (0.00) (0.00) (0.00)
Net Cash Flow - Financing 0.33 5.41 0.00 6.51 12.25

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference